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Abstract 
Introduction: Limited information is available about outcomes of patients with malignant 
adenomas endoscopically resected at screening. The aim of the study was to evaluate diagnostic and 
therapeutic quality indicators and to correlate them with clinical and surgical outcomes. 
Materials and Methods: We reviewed endoscopic and histology characteristics of all pT1 tumours 
endoscopically removed at the time of colonoscopy assessment in subjects with a positive 
screening test result in the context of a population-based program.  
Results: 392 pT1 tumours were completely removed by endoscopy (en-bloc= 86.7%, piecemeal= 
13.3%) and the histology report was considered complete in 83.2% of cases. Treatment was limited 
to endoscopic excision for 120 patients (30.7%, Group 1), 272 (69.3%, Group 2) underwent 
radicalisation surgery. In patients who had at least 1 lymph node examined, the rate of nodal 
involvement was 5.4% (13/239); no metastatic node was found in the 21 (27.6%) out of 76 patients 
with low-risk adenomas, who underwent surgery.  
Conclusion: Risk of nodal involvement in colorectal pT1 tumours is well predicted by known 
histologic features also in a screening setting, although it was lower than among patients from 
clinical series. Surgical overtreatment is still significantly present and there is ample room for 
improvement regarding diagnostic and therapeutic flow-chart.   
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1 Introduction 
Following the implementation of national colorectal cancer (CRC) screening campaigns, the 
incidence of malignant polyps, defined by submucosal invasion of cancer cells (pT1), is increasing 
[1,2]. The management of these cancerized adenomas is controversial and limited evidence is 
available about the long-term outcomes of patients with malignant polyps who undergo endoscopic 
removal in a screening setting, with or without subsequent surgical resection.  Usually, additional 
surgery with lymph nodes (LN) dissection is required only for patients who present one or more 
adverse histological criteria [3]; according to these criteria, malignant polyps are stratified into 2 
categories: 1) high risk for LN metastasis (poor differentiation, vascular or lymphatic invasion, 
margins of excision involved, presence of tumour budding, depth of tumour invasion >1000 µm) [4-
8]  2) low risk for LN metastasis (absence of any of the abovementioned factors). However, there 
are cases where - even though potential risks for LN metastasis are not present – additional surgery 
is performed, as well as cases at high risk for LN metastasis not treated by additional surgical 
resection.  Although surgery allows precise staging and treatment of both local and LN disease, it 
does harbour a definite risk of morbidity and mortality, especially in elderly patients, or in those 
with rectal disease [9]; for this reason, surgical radicalisation in low risk patients is not 
recommended.  On the other hand, post-polypectomy surgical under-treatment in high risk patients 
may determine a poorer oncologic outcome although the quality of surgical procedures in these 
patients is not homogeneous and LN harvesting (at least 12 LNs examined) is often sub-optimal 
[10-15]. 
To assess the post-polypectomy oncological outcome of patients with pT1 malignancy 
recruited during CRC screening, we conducted a retrospective analysis aimed to assess the 
relationship of the characteristics of the lesion with the risk of recurrence and disease-free survival, 
as well as to evaluate quality indicators of endoscopic and surgical management.  
 
 
  
2 Material and methods 
We retrospectively evaluated data on all consecutive colorectal pT1 tumours removed by 
endoscopy between 2004 and 2014 in the context of seven centres in the Piedmont Regional 
screening program in North-Western Italy. Details of screening program were previously reported 
[16]. Briefly, the Piedmont program has adopted flexible sigmoidoscopy (FS), offered once in the 
life-time at age 58, as the primary screening test; subjects refusing FS, or those older than 58 at the 
starting date of the program, are offered biennial fecal immunochemical test (FIT) until age 69. 
General practitioners are asked to exclude from invitation subjects with personal, or family (>1 first 
degree relative with CRC, or hereditary syndrome) history of CRC, personal history of 
inflammatory bowel disease, severe psychiatric symptoms, or those unable to provide informed 
consent.  
2.1 Screening procedure. FS exams are performed in hospital endoscopy units, by experienced 
gastroenterologists. Subjects detected at FS with one polyp ≥ 10 mm, or one advanced adenoma, or 
> 2 adenomas, are referred for total colonoscopy (TC) assessment.  
The FIT system (OC-Sensor, Eiken, Tokyo, Japan) adopted in the program is an automated 
quantitative immuno-turbidimetric assay performed over a single sample with a 20 µg Hb/gr faeces 
positivity cut off. 
All eligible subjects receive a personal invitation letter and those with a positive screening 
test results are contacted by the screening staff and they are offered an appointment for a TC. 
Patients in whom a CRC is detected are eventually referred for surgical treatment within the same 
hospital where the screening endoscopy unit is located. Within the Italian NHS, screening, 
assessment and treatment are free of charge for the patient, who can also choose an assessment 
centre different form the one indicated by the screening program. 
The inclusion criterion for the analysis was complete treatment for malignant pT1 polyps 
with endoscopic resection as the first line of treatment. Data on patient’s demographics, TC quality, 
number and site of removed polyps, type of polypectomy, immediate complications of 
  
polypectomy, characteristics of detected lesions, as well as stage of screen detected CRC, type of 
surgical intervention, number of LNs examined, are routinely recorded on the screening data base. 
For the purposes of this analysis we performed a record linkage of the screening data base with the 
regional hospital discharge records database to assess the frequency of late complications of the 
endoscopic procedure, of complications of surgical interventions, as well as CRC recurrence 
rate. Immediate and 30-day complications of surgery were classified according to Clavien’s 
classification [17].  The vital status at the end of follow-up period was ascertained for all trial 
subjects through an automated record linkage with the regional mortality registries, which 
also record the causes of death. Cancer-free survival and overall survival were also assessed. 
The cancerized adenomas were classified as lesions at low/ high risk for LN metastasis according to 
international guidelines present at the time of diagnosis [18,19]; classification has changed 
throughout the years and – consequently – the histological reporting form of endoscopically 
removed lesions has changed. At the beginning of the screening program, the malignant polyps 
were considered as lesions at low risk for LN metastasis if the following criteria were fulfilled: 1) 
complete resection with no margin involved  2) not poorly differentiated lesion  3) no vascular or 
lymphatic involvement.  Since 2010, two more features were considered: 1) no tumour budding  2) 
absence of submucosal invasion ≥ 1 mm.  For this reason, we retrieved for all cases the pathology 
report which was re-evaluated according to the new criteria by a gastroenterology trainee under the 
supervision of a pathologist with special interest in gastrointestinal pathology and our final analysis 
considered high risk lesions those showing at least one of the five abovementioned features.    
According to the screening protocol, no additional surgery was required if the polyp was at low risk 
for LN metastasis and was completely removed endoscopically.  Patients with high risk lesions had 
to undergo segmental colon resection following standard oncologic principles and conforming to 
guidelines recommending removal and examination of at least 12 LNs [20]. 
  
Residual disease was defined as the presence of any residual carcinoma at the site of polypectomy.  
Recurrence of disease was defined as the presence of locally, or regionally recurrent, disease, or 
distant metastases after a curative resection.   
We present monitoring data for a national health service program. The mandate of the program 
includes the follow-up of the participating subjects of all stages of the screening process. All the 
participating subjects sign, in each phase of the program (first and second level), a contribution that 
also includes access to the clinical documentation for the program monitoring procedures. For these 
activities it was therefore not foreseen, at least during the period of study recruitment (until 2014), 
an approval by ethics committees. This is an institutional mandate. The study protocol conforms to 
the ethical guidelines of the 1975 Declaration. 
 
2.2 Statistical analysis. Chi-square tests were used for comparisons of proportions and t-tests for 
comparisons of means (for continuous variables). Univariate and multivariable odds-ratios (OR) 
were estimated using logistic regression models, to assess predictors of surgical referral and surgical 
complications. Disease free and overall survival were estimated for endoscopy and surgical patients 
using the Kaplan-Meier method. For the purposes of this analysis each subject contributed to the 
follow-up from the date of treatment to the date of recurrence, emigration, or death, or to December 
31st 2014, whichever came first. To achieve a more reliable estimate of the risk of recurrent disease, 
we run also a sensitivity analysis excluding patients not diagnosed with a recurrence, who had not 
cumulated a minimum follow-up time of 24 months. All tests were 2-sided and statistical 
significance was set at 0.05. 
 
 
 
 
 
  
3 Results 
In the ten-year period under consideration, a total number of 520 malignant pT1 polyps in 
520 patients were observed; of these, 128 (24.6%) were referred for direct surgical intervention and 
were not included in the analysis. The indications for direct surgery were: size of the lesion, 
depressed morphology, no-lifting sign, technical problems during endoscopic resection. 
Of the remaining 392 malignant polyps, 340 (86.7%) were resected en-bloc and 52 (13.3%) by 
piece-meal technique.  According to subsequent histological evaluation, 250 (63.8%) patients were 
considered at high risk for LN metastasis, or residual disease at the site of polypectomy, 76 (19.4%) 
at low risk and in 66 (16.8%) risk stratification was not possible due to sub-optimal histologic 
sample or incomplete histology report. In particular, out of 340 en-bloc removed lesions, 230 
(67.6%) showed one, or more, high risk parameters, 67 (19.7%) could be classified in the low-risk 
group, while the level of risk could not be assessed in 43 (12.6%) cases with incomplete pathology 
report; the corresponding figures for the 52 polyps resected by piece-meal technique were 20 
(38.5%), 9 (17.3%) and 23 (44.2% -  OR for incomplete report: 0.18, 95% IC: 0.09-0.36; reference 
en-bloc). Out of 392 patients with endoscopically removed polyps, 120 (30.7%) did not undergo 
further treatments (Group 1) and 272 (69.3%) were referred for radicalisation surgery (Group 2). 
Demographic, clinical and procedural characteristics in both groups are shown in Table 1. 
 
Table 1 
 
No significant differences were found for age and gender. In patients who underwent radicalisation 
surgery, lesion size was significantly larger; right colon localization and sessile/flat morphology 
were significantly more frequent. Fifty-five patients in Group 1 (45.8%) were considered at high 
risk for LN metastases according to the new criteria, but 34 of them (61.8%) showed low risk 
parameters according to international guidelines present at the time of diagnosis; the remaining 21 
patients refused surgery, or had significant comorbidities contraindicating surgery. 
  
Out of 272 patients in Group 2, 195 (71.6%) showed high-risk and 21 (7.8%) low-risk histological 
features following endoscopic resection, while 56 (20.6%) had an incomplete histology report. At 
multivariable analysis (Table 2), factors independently associated with surgery referral were female 
sex, size larger than 25 mm, non-pedunculated shape, proximal site and the high-risk histology 
features.  
 
Table 2. 
 
3.1 Endoscopy quality indicators. Out of 392 patients undergoing endoscopic resection, 1 
(0.26%) suffered from bleeding requiring hospitalization; no late complication of endoscopy 
was observed among the 120 patients who were not referred for surgery.   
 
3.2 Surgery quality indicators. Thirty-eight of 272 patients (13.9%) sent to radicalisation surgery 
showed residual disease at the site of polypectomy and all of them belonged to the high-risk group. 
One more patient showed liver metastases, but no neoplastic LNs at the moment of surgery. 
The median number of retrieved LNs per patient was 9 (mean: 9.89); a minority of patients had no 
LNs observed in the specimen (33, 12.1%), 73 (26.8%) had less than 7 LNs removed, 77 (28.3%) 
had 7-11 LNs removed and 89 (32.7%) ≥ 12 LNs.   
Post-surgery complications were documented in 42 out of 272 patients (15.4%) (Table 3); 35 
(83.3%) occurred immediately, or within 30 days after surgery, while 7 (16.7%) were observed after 
30-days post-surgery.  
 
Table 3. 
 
Women seemed less prone to develop complications (OR: 0.30, 95% IC 0.16-0.58) while removal 
of ≥7 LNs was associated to a higher risk of complications (OR: 2.60, 95% IC 1.26-5.37).  There 
  
were no deaths related to surgery, but 5 (11.9%) patients had to undergo a second surgical 
procedure.   
3.3 Residual disease and nodal involvement. In patients who underwent surgical resection and 
had at least 1 LN examined (239), the rate of LN positivity was 5.4% (13/239), but if only high-risk 
patients are considered, the rate increased up to 6.3% (11/173). Correlation between number of 
removed LNs and prevalence of neoplastic positivity stratified according to the risk class is reported 
in Table 4.   
 
Table 4. 
 
No positive LN was observed among low risk patients, irrespective of the number of retrieved LNs. 
Among high risk patients, those who had more than 6 LNs removed showed more frequently LN 
metastases (7.7%) compared with patients with lesser LNs retrieved (3.5%) (this difference was not 
statistically significant).  
Residual disease in the bowel wall was observed in 13.8% of patients undergoing surgical resection: 
it was less frequent among subjects who had their lesion resected en bloc (10.4% as compared to 
piece-meal 33.3%; OR:0.23, 95%CI:0.10-0.54) and, among subjects with en-bloc resection, among 
those detected with pedunculated lesions (5.4% as compared to sessile 16.8%; OR:0.28, 
95%CI:0.10-0.77).  
Nodal involvement was more frequent (OR: 5.79; 95%CI:1.84-21.38) among subjects with residual 
disease (6 out of 38 patients, 15.8% versus 7 out of 223 patients, 3.1%);  
Adjusting for age, gender and size of the lesion (Table 5), excision technique and morphology of 
the lesion emerged as predictors of residual disease, which was less likely when the lesions had 
been excised en-bloc (OR: 0.23; 95%CI: 0.10-0.54), as opposed to piecemeal resection, and, among 
lesions resected en-bloc, for pedunculated (OR: 0.28; 95%CI: 0.10-0.77), as compared to sessile/flat 
lesions. 
  
 
Table 5. 
 
3.3 Follow up. The mean follow-up time was 53.4 months (±33.4) in Group 1 and 57.1 months 
(±31.1) in Group 2. The follow-up protocol included an early endoscopic control (within 6 months) 
followed by a TC at 1-3 years. No recurrence was observed among the 55 low-risk patients treated 
by endoscopic resection alone, as well as among the 21 low-risk patients and the 56 patients with 
undetermined histologic features, who underwent additional surgery after endoscopic resection. 
Recurrence free survival was similar for the two groups [Figure 1]: for the high-risk patients with 
radicalisation surgery, the recurrence rate was 1.5% (3/195); in each of them (100%), ≤7 LNs were 
removed during surgery; among patients with polypectomy only, one out of 55 high risk patients 
(1.8%) and one of 10 patients (10%) with incomplete histologic features showed neoplastic 
recurrence: both had refused surgery.  
 
Figure 1. 
 
Of the 272 patients who underwent surgery, 2 (0.7%) died from unrelated causes, while 3 (1.1%) 
died of disease progression (1 from local recurrence and 2 of metastatic disease): all belonged to the 
high-risk group. Among Group 1, 5 (4.1%) patients died from unrelated causes, none of disease 
progression. 
 
 
 
 
 
 
  
4 Discussion 
Our study showed a good oncologic outcome in patients with pT1 malignant polyps 
endoscopically removed during colorectal cancer screening confirming previous population-based 
data [21]. In particular, the results of this study indicate that in malignant polyps considered safe to 
be removed endoscopically by current guidelines [19], no LNs metastasis was observed during 
follow up with a recurrence-free survival rate of 100%.   
Only two patients, out of 120 not referred for surgery, showed disease progression: one 
could be classified in the high-risk group, when considering those histological features introduced 
more recently, while in the second case the histology report was not including the necessary 
information to classify patient’s level of risk. Among patients undergoing surgery, disease 
recurrence was found in 3 patients (1.5%) and all of them had high-risk malignant polyps.  
CRC related deaths (due to disease progression) were observed only among Group 2 patients, while 
overall mortality was slightly higher in group 1 (4.1%) than in group 2 (1.8%), possibly as a result 
of higher prevalence of co-morbidity, contraindicating surgery; however, the difference did not 
reach the level of statistical significance. 
Compared to previous studies on population-based data [6,22-23], we found a low rate (6.3%) of 
nodal metastases among subjects with lesions showing high-risk histological features as well as a 
low risk of residual disease among subjects with pedunculated lesions. 
As compared to other similar studies, the direct surgery referral rate was higher both in a 
multicenter analysis of 5 screening programs [24] in North-Eastern Italy (30%) and in the UK [25] 
bowel cancer screening program (43%), with a lower referral rate for radicalisation surgery (57% 
and 53% respectively, as compared to 69%); the overall recurrence rate was similar in our program, 
as in the Italian multicenter study (1.3%), while it was higher (3.2%) in UK bowel screening 
program, over a shorter follow-up interval. Mortality data are comparable in our study as in the 
other reports from screening [24,25] or clinical settings [22].  The incidence of residual disease in 
the subgroup of patients undergoing surgical intervention after endoscopic resection was 
  
within the range observed in other studies conducted in screening settings in North-Eastern 
Italy [24] and in UK [25]. A higher frequency of residual disease has been reported in clinical 
[26-28] and population based [29] series. 
However, the adoption of different definitions (including only residual disease in the bowel 
wall, or also nodal metastases) limits the comparability of the reported findings. Also, the 
diffusion of screening, as well as the improvement of endoscopic techniques are likely to 
influence the pattern of presentation of the disease. Screen detected cases might show more 
favourable prognostic parameters (nodal involvement in pT1 CRCs seems less frequent in 
more recent screening series [24,25] as compared to reports dating back to the pre-screening 
era [26-28]) while the lower risk of recurrence observed among patients with sessile lesions in 
the more recent years [29] would suggest that excision technique has improved over time.  
Our results are confirming that efforts to improve quality of pathologic evaluation and 
reporting of histologic specimens are needed also in the screening setting, as recently reported by an 
Italian study [30]. In spite of recommendations of the screening protocol and of EU and GISCoR 
guidelines, only a minority (<25%) of specimens related to malignant polyps were reviewed for a 
second opinion by a pathologist with a special interest in gastrointestinal pathology.  
Also, about 16.8% of removed polyps had an incomplete histology report, in most cases related to 
lacking data from pathologic examination. The great majority of these patients (84.8%) underwent 
surgery showing a LNs positivity rate of 3.5%, suggesting that many of them probably had low risk 
malignant polyps.  
An accurate pathology report was not necessarily taken into account when making decisions about 
patient’s management. We still observed a fairly high surgery referral rate (27.6%) among patients 
with well characterised low-risk cancerized adenomas. Many studies [21,22,31,32] documented that 
endoscopic removal of these lesions is associated with very low rates of recurrence and with a high 
disease-free and overall survival, often approaching 100% at five-year follow-up, while surgical 
treatment may be associated with a high potential for morbidity. According to our data, about 15% 
  
of patients experienced post-surgery complications, with a significant increase of direct and indirect 
costs.    Post-polypectomy and post-surgery complications rates observed in our patients are 
comparable with those reported by other studies [21,33,34] addressing the clinical and 
surgical outcomes in carriers of malignant colonic polyps.   
In our series the mean number of resected LNs at surgery was below the threshold indicated by 
guidelines [20] which suggest a minimum number of 12. Although other studies [33,35,36] have 
previously suggested that less than 12 LNs may be sufficient to adequately stage pT1 colon cancer, 
the rate of LN evaluation in our study (< 7 LNs in about 40% of patients) is probably inadequate. 
We are not able to explain this dismal LN evaluation which also has implications for adjuvant 
therapy discussions as well as cancer surveillance after resection.  
This study has certain limitations. First, it is a retrospective study of clinical records; 
however, the data are likely to be reliable because all patients with malignant polyps removed by 
endoscopy at 7 Screening Centres between 2004 and 2014 were included and no one was lost to 
follow up. The second limitation is that it was not randomized; however, we think that the possible 
selection bias is minimal because the patients’ characteristics and the median follow-up periods 
were not significantly different between the 2 groups.    
In conclusion, the results of our study can be summarized as follows.  First, in a screening 
setting, the oncologic outcome of patients with malignant pT1 polyps removed by endoscopy is 
excellent. Second, there is ample room for improvement regarding diagnostic accuracy, in order to 
reduce surgical overtreatment. Third, quality of surgical resection as measured by LNs counts is still 
sub-optimal and rigorous adherence to guidelines concerning LNs harvesting is strongly 
recommended to decrease the recurrence risks. 
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Figure 1. Recurrence free survival by type of treatment (Log-rank test p =0.80) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1. Baseline characteristics of patients and polyps 
 
 
Polypectomy only 
(n = 120) 
Radicalisation surgery 
(n = 272) 
OR (95%CI); p 
 
Age (mean ± SD) 64.45 (± 4.25) 64.74 (± 4.46) p = 0.54 
    
Gender 
Male (n, %) 
Female (n, %) 
   
86 (71.6%) 167 (61.4%) 
1.5 (0.97 - 2.71) 
34 (28.4%) 105 (36.6%) 
    
Site 
Right colon 
Left colon 
Rectum 
   
14 (11.7%) 55 (20.2%) 1.94 (1.02 – 3.69) 
86 (71.7%) 174 (64%) 1 
20 (16.6%) 43 (15.8%) 1.06 (0.50-1.92) 
    
Size (mm, mean ± SD) 16.13 (± 7.90) 20.14 (± 12.69) p = 0.002 
    
Morphology 
Pedunculated 
Sessile/flat 
   
87 (72.5%) 141 (51.8%) 
2.45 (1.50 – 4.01) 
33 (27.5%) 131 (48.2%) 
    
LNs metastases risk    
High risk 55 (45.8%) 195 (71.7%) 9.29 (5.17 – 16.67) 
Low risk 55 (45.8%) 21 (7.8%) 1 
Undetermined 10 (8.4%) 56 (20.5%) 14.67 (6.33 – 33.97) 
OR = odd ratio; CI = confidence interval; p = p value; SD = standard deviation 
  
Table 2. Multivariate analysis of factors associated with radicalisation surgery 
 
Features OR* 95%CI 
Gender 
Male  
Female  
  
1 
1.05 – 3.02 
1.78 
Age    
< 65 years 1 
0.56 – 1.52 
> 65 years 0.92 
Polyp size 
1-15 mm 
16-25 mm 
> 25 mm 
  
1  
1.17  0.68 – 2.02 
2.9 1.46 -  5.78 
Polyp morphology   
Sessile/flat 1 
0.21 – 0.51 
Pedunculated 0.35 
LNs metastases risk   
Undefined risk 1   
Low risk 0.17 0.09 – 0.31 
High risk  2.01 1.03 – 3.90 
Site   
Distal 1  
Proximal 2.13 1.08 – 4.24 
*ORs adjusted for all the variables n the model 
  
Table 3. Postoperative complications according to Clavien’s classification 
 
Post-surgical outcomes Number of patients 
Clavien grade I  
Abdominal pain 1 
Vomiting  2 
Biliary colic 2 
Symptomatic hyperuricemia 1 
Not specified 3 
Clavien grade II  
Wound infection 7 
Urinary infection 2 
Acute pancreatitis 
Pneumonia 
1 
2 
Clavien grade III 
Gastrointestinal bleeding 11 
Incisional hernia 3 
Clavien grade IV  
Anastomotic leakage 2 
Myocardial infarction 1 
Hemoperitoneum 1 
Pulmonary embolism 2 
Anastomotic stenosis 1 
 
 
 
  
Table 4. Pre-surgery histological risk parameters: correlation between number of LNs removed and 
nodal involvement 
 
 Number of LNs removed 
 < 7 7-11 ≥ 12 
 
Low-risk patients 
 
9 
 
3 
 
9 
Positive LNs (n, %) 0 (0%) 0 (0%) 0 (0%) 
    
High-risk patients 79 60 56 
Positive LNs (n, %) 2 (2.5%) 5 (8.3%) 4 (7.1%) 
    
Incomplete/undetermined report 18 14 24 
Positive LNs (n, %) 0 (0%) 0 (0%) 2 (8.3%) 
 
  
Table 5. Multivariate analysis of predictors of risk of residual disease 
 
Features OR* 95%CI 
Gender 
Male  
Female  
  
1 
0.29 - 1.50 
0.66 
Age   
< 65 years 1 
0.35 - 1.58 
> 65 years 0.74 
Polyp size 
1-15 mm 
16-25 mm 
> 25 mm 
 
1  
1.10  0.39 - 3.14 
3.58 1.46 -  8.81 
Polyp morphology  
Sessile/flat 1 
0.15 – 0.76 
Pedunculated 0.34 
Resection   
En-bloc 1  
Piece-meal 3.25 1.42 – 7.43 
*ORs adjusted for all the variables in the model 
 
